Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.43 |
| ▸ | DPP4 | P27487 | 3/20 | 0.41 |
| ▸ | METAP1 | P53582 | 1/20 | 0.38 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 4/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SI | P14410 | 1/20 | 0.33 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23165799 | 1.00 | EPHX2 (0.43) | EPHX2DPP4METAP1TET2TSHR | |
| SCHEMBL4450020 | 0.92 | — | — | |
| Hydrochloric Acid SCHEMBL76321 | 0.90 | EPHX2 (0.47) | EPHX2DPP4METAP1TET2TSHR | |
| SCHEMBL13450036 | 0.84 | EPHX2 (0.43) | EPHX2METAP1TET2TSHRRECQL | |
| SCHEMBL7440501 | 0.83 | EPHX2 (0.55) | EPHX2DPP4TET2TSHRRECQL | |
| SCHEMBL1977433 | 0.83 | EPHX2 (0.59) | EPHX2DPP4DPP7KDM4EPOLB | |
| SCHEMBL16374968 | 0.82 | SMYD3 (0.43) | EPHX2METAP1TET2TSHRRECQL | |
| SCHEMBL2411177 | 0.82 | EPHX2 (0.62) | EPHX2DPP4DPP7KDM4EPOLB | |
| Hydrochloric Acid SCHEMBL6871695 | 0.82 | EPHX2 (0.58) | EPHX2DPP4DPP7KDM4EPOLB | |
| SCHEMBL18845118 | 0.82 | EPHX2 (0.62) | EPHX2DPP4DPP7KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220389009-A1 | SUBSTITUTED 1,6-NAPHTHYRIDINE INHIBITORS OF CDK5 | GFB (ABC), LLC | 2022-12-08 | — | — | US | disclosed |
| EP-4037683-A1 | SUBSTITUTED 1, 6-NAPHTHYRIDINE INHIBITORS OF CDK5 | Goldfinch Bio, Inc. (US) | 2022-08-10 | — | — | EP | disclosed |
| WO-2021067569-A1 | SUBSTITUTED 1, 6-NAPHTHYRIDINE INHIBITORS OF CDK5 | GOLDFINCH BIO, INC. (US) | 2021-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220389009-A1 | SUBSTITUTED 1,6-NAPHTHYRIDINE INHIBITORS OF CDK5 | CDK5, CDK5R1, PKD1 | EPHX2 4364/4885DPP4 3949/4885METAP1 2714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.